Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) Jg. 373; H. 9670; S. 1183 - 1189
Hauptverfasser:	Conde, Marcus B, Efron, Anne, Loredo, Carla, De Souza, Gilvan R Muzy, Graça, Nadja P, Cezar, Michelle C, Ram, Malathi, Chaudhary, Mohammad A, Bishai, William R, Kritski, Afranio L, Chaisson, Richard E
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Kidlington Elsevier Ltd 04.04.2009 Elsevier Elsevier Limited
Schlagworte:	Adult Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Aza Compounds - adverse effects Aza Compounds - therapeutic use Bacterial diseases Biological and medical sciences Brazil - epidemiology Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Ethambutol - adverse effects Ethambutol - therapeutic use Female Fluoroquinolones General aspects Human bacterial diseases Humans Infectious diseases Internal Medicine Isoniazid - therapeutic use Kaplan-Meier Estimate Logistic Models Male Medical sciences Moxifloxacin Multivariate Analysis Mycobacterium tuberculosis Pyrazinamide - therapeutic use Quinolines - adverse effects Quinolines - therapeutic use Rifampin - therapeutic use Sputum - microbiology Time Factors Treatment Outcome Tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis, Pulmonary - diagnosis Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology Tuberculosis, Pulmonary - mortality Brazil Brazil, Rio de Janeiro Mycobacterial infection Moxifloxacin Infection Medicine Fluoroquinolone derivatives Treatment Tuberculosis Phase II trial Bacteriosis Clinical trial Ethambutol Antituberculous agent Antibacterial agent Quinolone derivatives Comparative study
ISSN:	0140-6736, 1474-547X, 1474-547X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!